Company Overview
Immunic, Inc. operates as a biotechnology entity focused on developing a pipeline of selective oral immunology therapies designed for the treatment of chronic inflammatory and autoimmune diseases within the United States and Germany markets. The company functions within the broader Healthcare sector, specifically targeting the specialized industry of Biotechnology, which implies a focus on research and development of biological drugs rather than traditional pharmaceutical manufacturing. As of the latest reporting data, Immunic, Inc. holds a market capitalization of $172.21M and employs 92 individuals to support its clinical and operational activities. The market cap figure of $172.21M, combined with the reported annual revenue of N/A, indicates that the company is a micro-cap entity where valuation is driven primarily by pipeline potential rather than current cash flows or sales volume. The absence of reported revenue alongside a positive market cap suggests the company is in a pre-revenue or early-stage commercialization phase where asset value is contingent upon the successful progression of its development programs.
Financial Health
The company reported revenue of N/A for the trailing twelve months, a net income of $-97,172,000, and an EBITDA of $-103,060,000. The significant gap between the reported revenue of N/A and the substantial net loss of $-97,172,000 reveals a cost structure dominated by high operational expenses, likely including clinical trial costs and research and development expenditures that exceed any current revenue generation. Free cash flow stands at $-50,656,500, which indicates that the company is burning cash at a significant rate, limiting its immediate financial flexibility and necessitating reliance on external capital sources to fund ongoing operations. The company maintains a cash balance of $15.48M against total debt of $577,000, resulting in a debt-to-equity ratio listed as N/A due to the financial constraints of the sector. The current cash position of $15.48M is significantly higher than the debt of $577,000, suggesting the balance sheet is structured to manage solvency despite the lack of profitability, though the low cash reserve relative to cash burn is a critical metric. The current ratio is 0.75, which indicates that the company's current assets are insufficient to cover its current liabilities without the need for additional financing or asset liquidation in the short term. Return on Equity is -1653.1% and Return on Assets is -198.8%, figures that reveal management is currently unable to generate positive returns on shareholder capital or the assets deployed, reflecting the typical financial profile of a biotechnology firm in the late clinical development stage.
Valuation Assessment
The trailing P/E ratio is N/A because the company has not generated net income, while the forward P/E is reported as -3.80, a metric that is technically invalid for valuation purposes but signals the market's expectation of continued negative earnings in the near term. The price-to-book ratio stands at -24.00, which indicates that the market is pricing the company well below its book value, a common occurrence for biotechnology firms with substantial intangible assets like intellectual property that are not fully captured in standard accounting book values. The price-to-sales ratio is N/A due to the lack of reported revenue, and the EV/EBITDA is -1.53, suggesting that traditional multiple-based valuation models are not applicable and that value is derived from pipeline milestones rather than cash flow multiples. The stock has traded between a 52-week high of $1.51 and a 52-week low of $0.51, and while the exact current price is not provided, the wide range demonstrates significant price volatility typical of small-cap biotechnology equities. The beta value is 1.48, which means the stock's price volatility is nearly 50% higher than the broader market, exposing investors to amplified market swings and increased risk during periods of market stress.
Growth & Income
Revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, meaning that growth rates cannot be calculated from the available trailing twelve-month data, but the context of a N/A revenue figure implies the company is not yet in a sustained growth phase defined by commercial sales. Because the company has not achieved profitability, a dividend yield of N/A and a payout ratio of 0.0% are reported, indicating that the firm does not distribute dividends to shareholders. Instead of paying dividends, the company reinvests all available earnings, including its cash reserves of $15.48M, back into the development of its lead program IMU-838 and the broader pipeline of selective oral immunology therapies. The overall growth and income profile is characterized by a complete absence of current income generation, with all financial resources directed toward advancing clinical development programs in Phase 3 and Phase 2 stages to achieve future commercial viability.